Extending Life For Pancreatic Cancer Patients

  • The FDA has approved Optune Pax (tumor treating electrical fields) in combination with gemcitabine and nab-paclitaxel for adults with unresectable, locally advanced pancreatic cancer, representing one of the first new treatment options for these patients in decades.
  • Treatment approval was based on Phase III results from the PANOVA-3 study, which showed a two month increase in overall survival (OS) and no prohibitive side effects. Study authors say adding Optune Pax could also lead to quality of life improvements for patients.
  • This is the latest case-use for the technology that is already commonly used in the treatment of glioblastoma (GBM).

The FDA’s recent approval of Optune Pax in combination with gemcitabine and nab-paclitaxel for adults with locally advanced pancreatic cancer brings a long-anticipated new option to a disease that has seen few therapeutic advances over the past three decades.

The approval is based on results from the Phase III PANOVA-3 trial and marks the expansion of Tumor Treating Fields (TTFields), a biophysical therapy delivered through a wearable device, into pancreatic cancer. For clinicians, it introduces a complementary treatment that works alongside chemotherapy without adding meaningful side effects.

The Data Behind The Approval

The PANOVA-3 study enrolled 571 patients with unresectable, locally advanced pancreatic adenocarcinoma. Patients were randomized to receive gemcitabine and nab-paclitaxel chemotherapy with or without TTFields delivered via Optune Pax.

Key findings included:

  • Median overall survival (OS) of 16.2 months with Optune Pax plus chemotherapy versus 14.2 months with chemotherapy alone.
  • In the modified per-protocol population (≥28 days of device use), median OS reached 18.3 months versus 15.1 months in the control arm.

Dr. Vincent Picozzi, a PANOVA-3 investigator and director of the Pancreaticobiliary Program at the Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center in Seattle, says the study was a significant step forward beyond the lengthened OS and lack of prohibitive toxicity.

“It also significantly extended time to pain progression, helping to preserve overall quality of life, which is a priority when I am treating patients living with pancreatic cancer,” Dr. Picozzi tells SurvivorNet Connect.

For a disease in which incremental gains are often measured in weeks, a two-month improvement in median OS, achieved without intensifying chemotherapy, is clinically meaningful.

Dr. Anna Berkenblit, the Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network, framed up the FDA approval as a major milestone for the pancreatic cancer community, saying “survival rates for pancreatic cancer have seen only modest improvements over time and treatment advances have remained limited, underscoring how challenging this disease is to treat. This approval for locally advanced disease highlights the importance of continued innovation and investment in new approaches for difficult‑to‑treat cancers and represents meaningful progress for patients who urgently need more options.”

How Optune Pax Works With Minimal Side Effects

Optune Pax delivers low-intensity, alternating electric fields through adhesive abdominal arrays. These TTFields interfere with mitotic spindle formation and other intracellular processes during cell division.

Because TTFields are physical rather than pharmacologic, they do not compound hematologic or gastrointestinal toxicities. Patients are generally advised to wear the device for approximately 18 hours per day, allowing continuous tumor-directed therapy while maintaining daily activities.

The most common adverse events reported were low-grade, manageable skin reactions beneath the arrays, consistent with prior TTFields experience in other tumor types.

Building on Optune’s Existing Track Record

While this is the first approval of TTFields in pancreatic cancer, the technology has been used for more than a decade in glioblastoma. SurvivorNet has extensively covered the role of Optune in brain cancer care, including how TTFields fit into the standard treatment paradigm.

Explore that coverage here:

In glioblastoma, TTFields added to maintenance temozolomide following surgery and radiation has been shown to improve progression-free and overall survival. That long-standing experience has helped cancer centers develop infrastructure around patient education, device support teams, and adherence monitoring, all of which will be important as pancreatic cancer programs begin integrating Optune Pax into practice.

Practical Considerations for Oncology Teams

For clinicians, successful implementation will likely focus on:

  • Appropriate patient selection: Adults with unresectable, locally advanced disease receiving first-line gemcitabine/nab-paclitaxel
  • Adherence counseling: PANOVA-3 suggests improved outcomes with sustained device use
  • Skin management protocols: Early dermatologic intervention can prevent treatment interruptions
  • Multidisciplinary coordination: Nursing, advanced practice providers, and device specialists will play key roles

Unlike many newly approved therapies, Optune Pax is home-based and does not add infusion time or additional clinic visits. That may ease workflow pressures while offering patients greater convenience.

SurvivorNet contributor Dr. Rodrigo C. Edelmuth, a Board Certified Digestive Surgeon at Hospital Israelita Einstein in Sao Paulo, Brazil says the FDA approval of Optune Pax is an important step forward, but cautions that clinicians need to be very honest and transparent with patients about what this treatment means in practice.

“Many of these patients already struggle with significant symptom burden including chronic pain, nutritional issues, and sometimes external drains or tubes. Adding a treatment that requires wearing a portable device continuously, with electrodes attached to the body and a battery system carried throughout the day [is] not a neutral intervention in their daily lives,” Dr. Edelmuth explains.

“For that reason, I strongly believe this should be a shared decision. Patients and their families need to clearly understand both the potential benefits and the practical implications of treatment, including the commitment required, the possible impact on daily activities, and the risk of skin-related side effects.”

A Meaningful Advance

Pancreatic cancer remains one of the most lethal solid tumors, with five-year survival rates still hovering in the low teens. According to information published by the National Cancer Institute, pancreatic cancer was expected to result in approximately 67,440 new diagnoses and 51,980 deaths in the U.S. in 2025.

Pancreatic cancer accounts for roughly 3.3% of all new cancer cases but represents a disproportionately large share of cancer deaths due to its late detection, aggressive disease behavior, and limited treatment options. For clinicians treating locally advanced pancreatic cancer, the Optune Pax approval represents another option and signals that biophysical therapies might now be used alongside other regimens in other difficult-to-treat cancers.